Pfizer Inc. (PFE)
NYSE: PFE · IEX Real-Time Price · USD
30.77
+1.01 (3.39%)
At close: Jul 26, 2024, 4:01 PM
30.69
-0.08 (-0.26%)
After-hours: Jul 26, 2024, 7:59 PM EDT
Pfizer Revenue
Pfizer had revenue of $14.88B in the quarter ending March 31, 2024, a decrease of -19.51%. This brings the company's revenue in the last twelve months to $54.89B, down -41.08% year-over-year. In the year 2023, Pfizer had annual revenue of $58.50B, down -41.70%.
Revenue (ttm)
$54.89B
Revenue Growth
-41.08%
P/S Ratio
3.16
Revenue / Employee
$626,068
Employees
88,000
Market Cap
174.36B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 58.50B | -41.83B | -41.70% |
Dec 31, 2022 | 100.33B | 19.04B | 23.43% |
Dec 31, 2021 | 81.29B | 39.64B | 95.16% |
Dec 31, 2020 | 41.65B | 746.00M | 1.82% |
Dec 31, 2019 | 40.91B | 80.00M | 0.20% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Elevance Health | 171.96B |
Sanofi | 50.96B |
Novartis AG | 48.86B |
Thermo Fisher | 42.49B |
Abbott Laboratories | 40.33B |
Amgen | 29.53B |
Danaher | 21.11B |
Stryker | 20.96B |
PFE News
- 10 hours ago - Will Pfizer Stock Post A Downbeat Q2? - Forbes
- 1 day ago - European Commission Approves Pfizer's DURVEQTIX® (fidanacogene elaparvovec), a One-Time Gene Therapy for Adults with Hemophilia B - Business Wire
- 2 days ago - UK regulator authorises Pfizer-BioNTech shot for JN.1 COVID variant - Reuters
- 2 days ago - Sangamo Stock Spikes As Pfizer Partnership Meets Goal In Late-Stage Study - Benzinga
- 2 days ago - Pfizer's gene therapy for rare genetic bleeding disorder succeeds in late-stage trial - CNBC
- 2 days ago - Pfizer's hemophilia A gene therapy found superior to current treatment in late-stage trial - Reuters
- 2 days ago - Pfizer announces positive results from late-stage trial of Hemophilia A treatment - Market Watch
- 2 days ago - Pfizer Announces Positive Topline Results From Phase 3 Study of Hemophilia A Gene Therapy Candidate - Business Wire